The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine

Influenza Clinical Trial

Official title:

A Single-centered, Open-labeled, Phase 4 Study of 2012-2013 Trivalent Seasonal Influenza Vaccine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01736709
• Other study ID #: PRO-INF-4012
• Status: Completed
• Phase: Phase 4
• First received: November 26, 2012
• Last updated: May 27, 2013
• Start date: November 2012
• Est. completion date: May 2013

Study information

• Verified date: November 2012
• Source: Sinovac Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the immunogenicity and safety of 2012-2013 trivalent seasonal influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy older people aged > 60 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 202
• Est. completion date: May 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 6 Months to 85 Years

Eligibility

For adults and old people:

Inclusion Criteria:

• Healthy adults aged 18-60 years old, and healthy old people aged >60 years

• Be able to show legal identity card for the sake of recruitment Without vaccination history of seasonal split influenza vaccine in the recent 3 years

• Not participate in any other clinical trials during the study

• Not receive any immunosuppressive agents during and one month prior to the study

• Be able to understand and sign the informed consent.

Exclusion Criteria:

• Woman: Who breast-feeding or planning to become pregnant during the study

• Any history of allergic reactions; was allergic to any component of the vaccine, such as eggs or ovalbumin

• Any history of severe adverse reactions to vaccines, such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain

• Autoimmune disease or immunodeficiency

• Acute episode of chronic diseases or conditions, including chronic hepatitis, hypertension, diabetes mellitus and cardiovascular diseases

• Guillain-Barre Syndrome

• Women subjects with positive urinary pregnancy test

• Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)

• Axillary temperature >37.0 centigrade at the time of dosing

• Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment

• Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

For infants:

Inclusion Criteria:

• Healthy male or female aged between 6 and 35 months

• Full-term birth, birth weight 2,500 grams or more

• provided birth certification or vaccination card Parent(s) or legal guardian(s) are able to understand and sign the informed consent

Exclusion Criteria:

• Administration of 2012-2013 seasonal vaccine

• Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc

• Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain

• Symptoms of acute infection within a week

• Autoimmune disease or immunodeficiency

• Congenital malformation, developmental disorders or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders)

• Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids

• Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with Intramuscular injections or blood draws

• History or family history of convulsions, epilepsy, brain disease and psychiatric

• Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen

• Guillain-Barre Syndrome

• History of any blood products within 3 months

• Administration of any other investigational research agents within 30 days

• Administration of any live attenuated vaccine within 30 days

• Administration of subunit or inactivated vaccines within 14 days

• Be receiving anti-Tuberculosis prophylaxis or therapy currently

• Axillary temperature > 37.0 centigrade at the time of dosing

• Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• 2012-2013 trivalent seasonal influenza vaccine
trivalent seasonal influenza vaccine with 0.25 ml / vial, for infants trivalent seasonal influenza vaccine with 0.5 ml / vial, for adults and old people

Locations

Country	Name	City	State
China	Henan Center for Diseases Control and Prevention	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hemagglutination inhibition (HI) antibody titer of 2012-2013 trivalent seasonal influenza vaccine	to evaluate the immunogenicity of the vaccine in adults and old people.	21 days after vaccination	No
Secondary	Frequency of systemic and local adverse reactions after vaccination	to evaluate the safety of the vaccine in healthy infants, adults, and old people	0-21 days after vaccination	Yes